The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Wei, Xiaolei ^a   Xu, Meng ^a   Wei, Yongqiang ^a   Huang, Fen ^a   Zhao, Tong ^a   Li, Xiangzhao ^a   Feng, Ru ^a   Ye, B Hilda ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Bone marrow involvement; CD44 variant isoforms; CHOP; DLBCL; Prognosis; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CD44V ANTIGEN; CD44V6 ANTIGEN; RITUXIMAB;

ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; EVENT FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD44; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROTEIN ISOFORMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 84899931212     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-34     Document Type: Article

References (11)

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C, N Engl J Med 2002 346 4 235 242 10.1056/NEJMoa011795 11807147
2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ, J Clin Oncol: Official J Am Soc Clin Oncol 2006 24 19 3121 3127 10.1200/JCO.2005.05.1003
3. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL), Lancet Oncol 2008 9 2 105 116 10.1016/S1470-2045(08)70002-0 18226581
4. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group, Lancet Oncol 2006 7 5 379 391 10.1016/S1470-2045(06)70664-7 16648042
5. Novel CD20 monoclonal antibodies for lymphoma therapy. Cang S, Mukhi N, Wang K, Liu D, J Hematol Oncol 2012 5 64 10.1186/1756-8722-5-64 23057966
6. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Sehn LH, Hematology Am Soc Hematol Educ Program 2012 2012 402 409 23233611
7. CD44: from adhesion molecules to signalling regulators. Ponta H, Sherman L, Herrlich PA, Nat Rev Mol Cell Biol 2003 4 1 33 45 10.1038/nrm1004 12511867
8. Alternative CD44 splicing in intestinal stem cells and tumorigenesis. Guo W, Frenette PS, Oncogene 2013
9. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JH, Pals ST, Leukemia 1990 4 8 595 599 1974938
10. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma. Inagaki H, Banno S, Wakita A, Ueda R, Eimoto T, Mod Pathol 1999 12 5 546 552 10349995
11. CD44 expression predicts disease outcome in localized large B cell lymphoma. Drillenburg P, Wielenga VJ, Kramer MH, van Krieken JH, Kluin-Nelemans HC, Hermans J, Heisterkamp S, Noordijk EM, Kluin PM, Pals ST, Leukemia 1999 13 9 1448 1455 10.1038/sj.leu.2401490 10482998